Clinical trial
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose…
NCT00033956 · MetaPhore Pharmaceuticals, Industry · Suspended
Key facts
| NCT number | NCT00033956 |
|---|---|
| Title | Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2 |
| Official title | Phase I/II Open Label Dose Escalation and Double-Blind, Placebo-Controlled Evaluation of M40403, for the Prevention of the Dose Limiting Toxicities of High Dose IV Bolus IL-2 Treatment of Metastatic Melanoma or Renal Cell Carcinoma. |
| Lead sponsor | MetaPhore Pharmaceuticals, Industry |
| Status | Suspended |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | IL-2 Induced Hypotension |
| Intervention type | Drug |
| Interventions | M40403 |
| Enrollment | 48 |
| Start date | Dec 1, 2001 |
| First posted | Apr 18, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: